Susquehanna International Group, LLP Essa Pharma Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.45 - $7.1 $80,100 - $127,800	-18,000 Reduced 54.38%	15,100 $91,000
Q2 2024 Aug 15, 2024	SELL	$4.63 - $8.42 $64,820 - $117,880	-14,000 Reduced 29.72%	33,100 $174,000
Q1 2024 May 07, 2024	BUY	$6.17 - $10.65 $5,553 - $9,585	900 Added 1.95%	47,100 $399,000
Q4 2023 Feb 14, 2024	BUY	$2.74 - $7.35 $126,588 - $339,570	46,200 New	46,200 $304,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.34 $157,300 - $202,070	-60,500 Reduced 83.91%	11,600 $31,000
Q1 2023 May 16, 2023	BUY	$2.56 - $3.55 $140,800 - $195,250	55,000 Added 321.64%	72,100 $214,000
Q4 2022 Feb 14, 2023	BUY	$1.5 - $4.82 $25,650 - $82,422	17,100 New	17,100 $43,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $71M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.